- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00590863
Combining Medications to Enhance Depression Outcomes (CO-MED)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The overall aim of Combining Medications to Enhance Depression Outcomes (CO-MED) is to enhance remission rates for outpatients with chronic or recurrent nonpsychotic major depressive disorder (MDD) as defined by DSM-IV TR, treated in primary or psychiatric care settings.
Current evidence indicates that remission, the goal of treatment, is found in only about one-third of representative depressed outpatients treated for up to 14 weeks with an initial SSRI. In addition, even for those who do respond or remit, over one-third relapse in the subsequent 12 months. Combinations of antidepressants are used in practice at the second or subsequent steps when relapse occurs in the longer term, or, in some cases, even acutely as a first step when speed of effect is a clinical priority. Whether such combinations could potentially offer higher remission rates, lower attrition, or greater longer-term benefit if used as initial treatments as compared to monotherapy remains to be examined.
CO-MED will test whether two different medications when given in combination as the first treatment step, compared to one medication, will enhance remission rates, increase speed of remission, be tolerable, and provide better sustained benefits in the longer term. Results of this study will inform practitioners in managing the treatment of patients with chronic or recurrent MDD.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alabama
-
Tuscaloosa, Alabama, United States, 35404
- Tuscalossa VA Mental Health Clinic
-
-
California
-
Harbor City, California, United States, 90710
- Harbor UCLA Family Health Care Center
-
Los Angeles, California, United States, 90024
- UCLA Internal Medicine Clinic
-
San Diego, California, United States, 92161
- Veterans Affairs Medical Center/FIRM Primary Care Clinic
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Psychiatric Outpatient Treatment Care Center
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Clinical Research Institute
-
-
Massachusetts
-
Salem, Massachusetts, United States, 01970
- MGH/Northshore Medical Center (Salem Psychiatric Facility)
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- General Psychiatric Ambulatory Clinic
-
-
New York
-
New York, New York, United States, 11040
- Irving Goldman Primary Care at North Shore Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7160
- UNC Chapel Hill Adult Diagnostic & Treatment Clinic
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74135
- Laureate Psychiatric Clinic and Hospital
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Bellefield Clinic of WPIC
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
- Vine Hill Community Clinic
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern Family Medicine Clinic
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- VCU Outpatient Psychiatry Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Seeking treatment at the primary or specialty care site, and be planning to continue living in the area of that clinic for the duration of the study
- Meets clinical criteria for nonpsychotic MDD, recurrent (with the current episode being at least 2 months in duration), or chronic (current episode greater than 2 years) as defined by a clinical interview and confirmed by the MINI International Neuropsychiatric Interview (MINI)
- Screening 17 item HRSD score of 16 or greater
- Treatment with antidepressant medication combinations is clinically acceptable
- Patient with and without current suicidal ideation may be included in the study as long as outpatient treatment is clinically appropriate
Exclusion Criteria:
- Pregnant or breastfeeding
- Plans to become pregnant over the ensuing 8 months following study entry or are sexually active and not using adequate birth control
- History (lifetime) of psychotic depression, schizophrenia, bipolar (I, II, or NOS), schizoaffective, or other Axis I psychotic disorders
- Current psychotic symptom(s)
- History (within the last 2 years before study entry) of anorexia or bulimia
- Current primary diagnosis of obsessive compulsive disorder
- Current substance dependence that requires inpatient detoxification or inpatient treatment
- Requiring immediate hospitalization for a psychiatric disorder
- Definite history of intolerance or allergy (lifetime) to any protocol medication
- History of clear nonresponse to an adequate trial of an FDA-approved monotherapy in the current MDE if recurrent, or during the last 2 years before study entry if chronic
- History of clear nonresponse to an adequate trial of any study medication used as a monotherapy, or to one or more of the protocol combinations in the current or any prior MDE
- Currently taking any of the study medications at any dose
- Having taken Prozac (fluoxetine) or an MAOI in the 4 weeks before study entry
- Presence of an unstable general medical condition (GMC) that will likely require hospitalization or to be deemed terminal (life expectancy less than 6 months after study entry)
- Currently taking medications or have GMCs that contraindicate any study medications (e.g., seizure disorder)
- Requiring medications for GMCs that contraindicate any study medication
- Epilepsy or other conditions requiring an anticonvulsant
- Lifetime history of having a seizure including febrile or withdrawal seizures
- Receiving or have received vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), or other somatic antidepressant treatments
- Currently taking or having taken within the 7 days before study entry any of the following exclusionary medications: antipsychotic medications, anticonvulsant medications, mood stabilizers, or central nervous system stimulants (antidepressant medication used for the treatment of depression or other purposes such as smoking cessation or pain are excluded since these agents may interfere with the testing of the major hypotheses under study)
- Uncontrolled narrow angle glaucoma
- Taking thyroid medication for hypothyroidism may be included only if stable on the medication for 3 months
- Using agents within the 7 days before study entry that are potential augmenting agents (e.g., T3 in the absence of thyroid disease, SAMe, St. John's Wort, lithium, buspirone)
- Therapy that is depression-specific
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: SSRI + placebo
Participants will take escitalopram plus placebo.
|
Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day).
Medications taken orally.
Participants will take escitalopram plus placebo for up to 28 weeks.
Dosages were adjusted as need at each clinic visit.
Other Names:
|
Active Comparator: Escitalopram + Bupropion SR
Participants will take escitalopram + bupropion-SR.
|
Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks.
Medications taken orally.
Bupropion SR was blinded, and escitalopram was given open label.
Dosages were adjusted as need at each clinic visit.
Other Names:
|
Active Comparator: Venlafaxine XR + Mirtazapine
Participants will take venlafaxine-XR + mirtazapine.
|
Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks.
Medications taken orally.
Venlafaxine XR was blinded, and mirtazapine was given open label.
Dosages were adjusted as need at each clinic visit.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quick Inventory of Depressive Symptoms
Time Frame: Measured at Month 7
|
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits.
QIDS depression scores range from 0 (normal) to 27 (very severe).
|
Measured at Month 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life Inventory
Time Frame: Measured at Month 7
|
The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health.
Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life.
It yields an overall raw score and satisfaction ratings for the 16 individual areas of life.
The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent.
Higher scores indicate higher reported quality of life.
|
Measured at Month 7
|
Collaborators and Investigators
Investigators
- Principal Investigator: Madhukar H. Trivedi, MD, University of Texas Southwestern Medical Center
- Study Director: Stephen R. Wisniewski, PhD, University of Pittsburgh
- Study Director: Diane Warden, PhD, MBA, University of Texas Southwestern Medical Center
- Study Director: Kathy Shores-Wilson, PhD, University of Texas Southwestern Medical Center
- Study Director: David W. Morris, PhD, University of Texas Southwestern Medical Center
Publications and helpful links
General Publications
- Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Shelton RC, Lesser IM, Kornstein SG, Wisniewski SR. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011 Jul;168(7):689-701. doi: 10.1176/appi.ajp.2011.10111645. Epub 2011 May 2.
- Olgiati P, Fanelli G, Atti AR, De Ronchi D, Serretti A. Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder. Int Clin Psychopharmacol. 2022 Nov 1;37(6):247-254. doi: 10.1097/YIC.0000000000000422. Epub 2022 Jul 12.
- Olgiati P, Serretti A. Persistence of suicidal ideation within acute phase treatment of major depressive disorder: analysis of clinical predictors. Int Clin Psychopharmacol. 2022 Sep 1;37(5):193-200. doi: 10.1097/YIC.0000000000000416. Epub 2022 Jul 7.
- Olgiati P, Fanelli G, Serretti A. Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features. Int Clin Psychopharmacol. 2022 Jul 1;37(4):166-172. doi: 10.1097/YIC.0000000000000396. Epub 2022 Feb 21.
- Olgiati P, Serretti A. Post-traumatic stress disorder and childhood emotional abuse are markers of subthreshold bipolarity and worse treatment outcome in major depressive disorder. Int Clin Psychopharmacol. 2022 Jan 1;37(1):1-8. doi: 10.1097/YIC.0000000000000380.
- Medeiros GC, Prueitt WL, Minhajuddin A, Patel SS, Czysz AH, Furman JL, Mason BL, Rush AJ, Jha MK, Trivedi MH. Childhood maltreatment and impact on clinical features of major depression in adults. Psychiatry Res. 2020 Nov;293:113412. doi: 10.1016/j.psychres.2020.113412. Epub 2020 Aug 18.
- Jha MK, Minhajuddin A, South C, Rush AJ, Trivedi MH. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. Am J Psychiatry. 2019 May 1;176(5):358-366. doi: 10.1176/appi.ajp.2018.18030355. Epub 2019 Mar 29.
- Sies A, Demyttenaere K, Van Mechelen I. Studying treatment-effect heterogeneity in precision medicine through induced subgroups. J Biopharm Stat. 2019;29(3):491-507. doi: 10.1080/10543406.2019.1579220. Epub 2019 Feb 22.
- De La Garza N, Rush AJ, Killian MO, Grannemann BD, Carmody TJ, Trivedi MH. The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. Depress Anxiety. 2019 Apr;36(4):313-320. doi: 10.1002/da.22855. Epub 2018 Oct 29.
- Gadad BS, Jha MK, Grannemann BD, Mayes TL, Trivedi MH. Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial. J Psychiatr Res. 2017 Nov;94:1-6. doi: 10.1016/j.jpsychires.2017.05.012. Epub 2017 May 26.
- Jha MK, Minhajuddin A, Gadad BS, Greer T, Grannemann B, Soyombo A, Mayes TL, Rush AJ, Trivedi MH. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology. 2017 Apr;78:105-113. doi: 10.1016/j.psyneuen.2017.01.023. Epub 2017 Jan 24.
- Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, Cannon TD, Krystal JH, Corlett PR. Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry. 2016 Mar;3(3):243-50. doi: 10.1016/S2215-0366(15)00471-X. Epub 2016 Jan 21.
- Warden D, Trivedi MH, Carmody T, Toups M, Zisook S, Lesser I, Myers A, Kurian KR, Morris D, Rush AJ. Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care. J Psychiatr Pract. 2014 Mar;20(2):118-32. doi: 10.1097/01.pra.0000445246.46424.fe.
- Toups MS, Myers AK, Wisniewski SR, Kurian B, Morris DW, Rush AJ, Fava M, Trivedi MH. Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication. Psychosom Med. 2013 Nov-Dec;75(9):863-72. doi: 10.1097/PSY.0000000000000000. Epub 2013 Oct 25.
- Sung SC, Haley CL, Wisniewski SR, Fava M, Nierenberg AA, Warden D, Morris DW, Kurian BT, Trivedi MH, Rush AJ; CO-MED Study Team. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. J Clin Psychiatry. 2012 Jul;73(7):967-76. doi: 10.4088/JCP.11m07043. Epub 2012 May 29.
- Morris DW, Budhwar N, Husain M, Wisniewski SR, Kurian BT, Luther JF, Kerber K, Rush AJ, Trivedi MH. Depression treatment in patients with general medical conditions: results from the CO-MED trial. Ann Fam Med. 2012 Jan-Feb;10(1):23-33. doi: 10.1370/afm.1316.
- Chan HN, Rush AJ, Nierenberg AA, Trivedi M, Wisniewski SR, Balasubramani GK, Friedman ES, Gaynes BN, Davis L, Morris D, Fava M. Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. Int J Neuropsychopharmacol. 2012 Nov;15(10):1387-99. doi: 10.1017/S1461145711001660. Epub 2011 Dec 1.
- Zisook S, Lesser IM, Lebowitz B, Rush AJ, Kallenberg G, Wisniewski SR, Nierenberg AA, Fava M, Luther JF, Morris DW, Trivedi MH. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. J Clin Psychiatry. 2011 Oct;72(10):1322-32. doi: 10.4088/JCP.10m06724.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agents
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Serotonin and Noradrenaline Reuptake Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors
- Serotonin 5-HT3 Receptor Antagonists
- Dopamine Uptake Inhibitors
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Adrenergic alpha-Antagonists
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Adrenergic alpha-2 Receptor Antagonists
- Citalopram
- Bupropion
- Dexetimide
- Venlafaxine Hydrochloride
- Mirtazapine
Other Study ID Numbers
- N01 MH090003-02
- DSIR AT (NCT00590863)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on SSRI + placebo
-
Baker Heart Research InstituteNational Health and Medical Research Council, AustraliaUnknown
-
Hoffmann-La RocheCompletedObsessive-Compulsive DisorderUnited States, Canada
-
University of Texas Southwestern Medical CenterNational Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
Shanghai Mental Health CenterUnknownMajor Depressive Disorder
-
All India Institute of Medical Sciences, BhubaneswarCompletedMajor Depressive DisorderIndia
-
Euthymics BioScience, Inc.CompletedMajor Depressive DisorderUnited States
-
University of Illinois at ChicagoNational Institute of Mental Health (NIMH); National Institutes of Health (NIH)CompletedInternalizing Psychopathologies (IPs) Depression and AnxietyUnited States
-
VA Office of Research and DevelopmentNot yet recruitingTraumatic Brain Injury (TBI)United States
-
National Institute of Mental Health (NIMH)WithdrawnDepression | Major Depression | Unipolar Depression | Anxiety Disorder
-
RenJi HospitalUnknown